Literature DB >> 10894458

Drug properties affecting aerosol behavior.

S Suarez1, A J Hickey.   

Abstract

The widespread use of aerosol therapy in the treatment of pulmonary diseases is based on optimizing drug properties and aerodynamic behavior of airborne particulates. In order to understand drug properties and aerodynamic behavior, it is important to recognize that each category of inhaler delivers a product with different physicochemical characteristics, and that these properties determine the site of deposition and the mechanism of clearance from the lungs. The complex interplay of these properties and the physiology and anatomy of the lungs must be considered to fully understand the implications for drug delivery. The aerodynamic behavior of aerosols under various inspiratory flow conditions influences the site of deposition. Once the particle comes to rest in the lungs, mechanisms of clearance are invoked, including dissolution and absorption, or, for more insoluble materials, mucociliary transport or cell-mediated transport. Finally the pharmacokinetics of drug disposition dictate the pharmacodynamic effects of the drugs responsible for efficacy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10894458

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  27 in total

1.  Development of a liposome formulation of ethambutol.

Authors:  Theresa Wiens; Thomas Redelmeier; Yossef Av-Gay
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

Review 2.  Carrier-based strategies for targeting protein and peptide drugs to the lungs.

Authors:  Sally-Ann Cryan
Journal:  AAPS J       Date:  2005-03-24       Impact factor: 4.009

3.  Inhalable powder formulation of pirfenidone with reduced phototoxic risk for treatment of pulmonary fibrosis.

Authors:  Satomi Onoue; Yoshiki Seto; Masashi Kato; Yosuke Aoki; Yoshiki Kojo; Shizuo Yamada
Journal:  Pharm Res       Date:  2013-02-21       Impact factor: 4.200

4.  Design, characterization, and aerosol dispersion performance modeling of advanced spray-dried microparticulate/nanoparticulate mannitol powders for targeted pulmonary delivery as dry powder inhalers.

Authors:  Xiaojian Li; Frederick G Vogt; Don Hayes; Heidi M Mansour
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2014-02-06       Impact factor: 2.849

5.  The Effect of Active Pharmaceutical Ingredients on Aerosol Electrostatic Charges from Pressurized Metered Dose Inhalers.

Authors:  Yang Chen; Paul M Young; David F Fletcher; Hak Kim Chan; Edward Long; David Lewis; Tanya Church; Daniela Traini
Journal:  Pharm Res       Date:  2015-03-19       Impact factor: 4.200

6.  Applicability of an ultrasonic nebulization system for the airways delivery of beclomethasone dipropionate in a murine model of asthma.

Authors:  Boska Hrvacić; Berislav Bosnjak; Marijan Tudja; Milan Mesić; Mladen Merćep
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

7.  Nanocomposite microparticles (nCmP) for the delivery of tacrolimus in the treatment of pulmonary arterial hypertension.

Authors:  Zimeng Wang; Julie L Cuddigan; Sweta K Gupta; Samantha A Meenach
Journal:  Int J Pharm       Date:  2016-08-26       Impact factor: 5.875

8.  Development of an Improved Inhalable Powder Formulation of Pirfenidone by Spray-Drying: In Vitro Characterization and Pharmacokinetic Profiling.

Authors:  Yoshiki Seto; Gen Suzuki; Sharon Shui Yee Leung; Hak-Kim Chan; Satomi Onoue
Journal:  Pharm Res       Date:  2016-03-14       Impact factor: 4.200

9.  Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer.

Authors:  Samantha A Meenach; Kimberly W Anderson; J Zach Hilt; Ronald C McGarry; Heidi M Mansour
Journal:  Eur J Pharm Sci       Date:  2013-05-23       Impact factor: 4.384

10.  Synthesis and Characterization of Nanocomposite Microparticles (nCmP) for the Treatment of Cystic Fibrosis-Related Infections.

Authors:  Zimeng Wang; Samantha A Meenach
Journal:  Pharm Res       Date:  2016-04-18       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.